Printer Friendly

FDA GRANTS EXPANSION OF SUMMIT'S PTK CLINICAL TRIALS

 WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Summit Technology, Inc. (NASDAQ: BEAM) announced today that the FDA has granted the company an expansion of its Phototherapeutic Keratectomy (PKT) clinical investigation. The expansion allows the treatment of an additional 390 patients while the FDA completes review of Summit's PMA application to market and sell its excimer laser system in the U.S. for PKT. Summit's PMA application for PTK was accepted for filing by the FDA in February, 1992. Summit believes that the FDA's permission to expand the company's PKT investigation is evidence of the promise that PKT holds for the treatment of corneal irregularities due to disease or injury.
 The company's U.S. clinical investigators have thus far treated over 350 PKT patients. It is neither intended nor required that the data from these additional 390 of patients will be submitted in support of the company's currently filed PMA application.
 Phototherapeutic keratectomy (PTK) treats corneal scars, dystrophies, recurrent erosions and other pathologic conditions of the cornea. In the United States alone, approximately 40,000 people have corneal transplants each year. The company believes that PTK may offer a better alternative to transplant surgery for many of these people and may successfully treat other conditions for which other surgical and medical therapies are now being employed with varying degrees of success.
 Representatives from the company will be attending an FDA panel meeting on Feb. 26, 1993 to discuss future PMA applications regarding laser refractive surgery. It is not anticipated that any discussions regarding current PMA's will take place.
 Summit Technology, Inc. has established the leadership position in designing manufacturing and marketing ophthalmic refractive laser systems where applications have been developed for the treatment of common vision disorders such as nearsightedness, farsightedness, astigmatism, glaucoma and certain corneal irregularities due to disease or injury.
 -0- 2/23/93
 /CONTACT: Paula Rainville, investor relations of Summit Technology, 617-890-1234/
 (BEAM)


CO: Summit Technology, Inc. ST: Massachusetts IN: MTC SU:

CH -- NE003 -- 9272 02/23/93 09:04 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 23, 1993
Words:331
Previous Article:DO'S AND DON'TS OF COMPLIANCE; DISABILITIES ACT VIDEO COULD AVOID LAWSUITS
Next Article:FLEET ANNOUNCES ONE OF THE LOWEST CREDIT CARD INTEREST RATES IN THE NORTHEAST
Topics:


Related Articles
SUMMIT SUBMITS PMA APPLICATION TO FDA FOR TREATMENT OF MYOPIA
FDA OPHTHALMIC ADVISORY PANEL RECOMMENDS APPROVAL OF SUMMIT TECHNOLOGY'S EXCIMER LASER SYSTEM FOR PTK
SUMMIT'S PMA APPLICATION FOR PHOTOREFRACTIVE KERATECTOMY (PRK) TO BE REVIEWED BY FDA OPHTHALMIC ADVISORY PANEL
SUMMIT TECHNOLOGY, INC. REPORTS FINANCIAL RESULTS FOR FY1994
SUMMIT RECEIVES AUTHORIZATION TO CONDUCT NEW CLINICAL TRIAL
SUMMIT RECEIVES FDA APPROVAL TO SELL EXCIMER LASER SYSTEM FOR PTK
CAROLINA EYE ASSOCIATES AMONG FIRST IN U.S. TO PERFORM MAJOR INNOVATION IN EYE SURGERY
SUMMIT ENFORCES INJUNCTION AGAINST CHIRON TECHNOLAS
SUMMIT TECHNOLOGY REPORTS THIRD QUARTER 1995 FINANCIAL RESULTS
Summit Receives FDA Approval to Expand Farsightedness Clinical Trials with Apex Plus Laser

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters